Non small cell lung cancer
Pro Research Analysisby 
Searched over 200M research papers
Epidemiology and Risk Factors of Non-Small Cell Lung Cancer (NSCLC)
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases and representing a major cause of cancer-related deaths worldwide 12310. The main risk factor for NSCLC is tobacco smoking, but other contributors include radon exposure, air pollution, and genetic predispositions 13.
NSCLC Subtypes and Molecular Diversity
NSCLC is a heterogeneous group of tumors, primarily including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Recent research highlights that adenocarcinomas and squamous cell carcinomas are distinct diseases at the molecular and clinical levels, with different genetic drivers and responses to treatment. This suggests that more subtype-specific approaches may improve outcomes .
Diagnosis and Staging of NSCLC
Most NSCLC cases are diagnosed at an advanced stage due to late symptom onset and insufficient screening programs, leading to poor prognosis 13. Diagnostic methods include chest X-ray, CT, PET imaging, and histological examination of tumor biopsies 14. Accurate staging, often using the TNM classification system, is essential for determining the best treatment strategy .
Advances in Screening and Early Detection
Systematic screening of high-risk populations with low-dose CT scans has improved early detection rates, allowing for earlier intervention and better outcomes 248. Liquid biopsy is also emerging as a non-invasive tool for diagnosis and monitoring .
Treatment Strategies for NSCLC
Surgery, Radiotherapy, and Chemotherapy
For early-stage NSCLC, surgery remains the primary treatment, sometimes combined with radiotherapy or chemotherapy. New surgical and radiotherapeutic techniques have improved safety and effectiveness 24. In locally advanced disease, combining perioperative strategies and adjuvant immunotherapy can enhance cure rates .
Targeted Therapy and Biomarker Testing
The discovery of specific genetic mutations, such as EGFR, ALK, ROS1, RET, BRAF V600E, MET, and NTRK, has led to the development of targeted therapies that significantly improve outcomes for patients with these alterations 1356+3 MORE. Biomarker testing is now standard practice to identify patients who may benefit from these treatments 78.
Immunotherapy
Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized the treatment of advanced and metastatic NSCLC, offering unprecedented survival benefits for selected patients 2568. These therapies are now a key part of the treatment landscape, especially for patients without actionable genetic mutations.
Palliative Care
Palliative care plays a central role in managing symptoms and improving quality of life for patients with advanced NSCLC .
Ongoing Challenges and Future Directions
Despite significant advances, overall cure and survival rates for NSCLC remain low, especially in metastatic disease 35. Continued research into new drugs, combination therapies, and individualized treatment approaches based on clinical and genetic markers is essential to further improve outcomes 258.
Conclusion
NSCLC is a complex and diverse disease with significant advances in screening, diagnosis, and treatment over the past decade. The integration of molecular testing, targeted therapies, and immunotherapy has transformed patient care, but ongoing research and personalized approaches are needed to further improve survival and quality of life for all patients with NSCLC 1235+2 MORE.
Sources and full results
Most relevant research papers on this topic